Shares of Insulet Co. (NASDAQ:PODD) have received a consensus recommendation of “Buy” from the twenty-two research firms that are presently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation, fourteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $79.00.
A number of equities analysts have recently commented on the stock. ValuEngine raised shares of Insulet from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Guggenheim assumed coverage on shares of Insulet in a research report on Tuesday, April 3rd. They issued a “buy” rating and a $105.00 price target on the stock. Oppenheimer set a $82.00 price target on shares of Insulet and gave the company a “hold” rating in a research report on Thursday, February 22nd. Stephens reissued an “equal weight” rating and issued a $81.00 price target (up previously from $60.00) on shares of Insulet in a research report on Thursday, February 22nd. Finally, BidaskClub raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 23rd.
Shares of NASDAQ:PODD traded down $0.62 during trading on Wednesday, reaching $85.53. The stock had a trading volume of 244,056 shares, compared to its average volume of 511,827. Insulet has a 52 week low of $38.43 and a 52 week high of $88.88. The firm has a market cap of $4,964.41, a price-to-earnings ratio of -186.41 and a beta of 1.38. The company has a quick ratio of 5.85, a current ratio of 6.24 and a debt-to-equity ratio of 3.57.
Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04). Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. The firm had revenue of $130.50 million during the quarter, compared to the consensus estimate of $125.16 million. During the same period in the prior year, the business earned ($0.16) EPS. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. research analysts predict that Insulet will post -0.29 EPS for the current fiscal year.
In other Insulet news, EVP Bradley A. Thomas sold 7,250 shares of the business’s stock in a transaction on Wednesday, March 14th. The shares were sold at an average price of $83.81, for a total value of $607,622.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David A. Lemoine sold 641 shares of the business’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total transaction of $49,235.21. The disclosure for this sale can be found here. Insiders sold a total of 28,800 shares of company stock worth $2,412,739 in the last three months. Insiders own 2.60% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Cerebellum GP LLC bought a new stake in Insulet in the 4th quarter valued at $122,000. Equitec Specialists LLC bought a new stake in Insulet in the 4th quarter valued at $145,000. James Hambro & Partners bought a new stake in Insulet in the 4th quarter valued at $165,000. C M Bidwell & Associates Ltd. bought a new stake in Insulet in the 4th quarter valued at $188,000. Finally, Diversified Trust Co bought a new stake in Insulet in the 4th quarter valued at $218,000.
COPYRIGHT VIOLATION WARNING: “Insulet Co. (PODD) Receives Average Rating of “Buy” from Analysts” was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/04/18/insulet-co-podd-receives-average-rating-of-buy-from-analysts.html.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.